Dupixent Lawsuit for T-Cell Lymphoma

Dupixent lawsuits are now moving forward in federal court for patients who allege the drug caused, accelerated, or unmasked cutaneous T-cell lymphoma and related T-cell lymphomas. On June 4, 2026, the Judicial Panel on Multidistrict Litigation centralized the federal Dupixent cases in MDL No. 3180, In re: Dupixent (Dupilumab) Products Liability Litigation, in the District of New Jersey before Judge Zahid N. Quraishi.

Dupixent, also known as dupilumab, is a biologic medication used to treat atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, COPD, bullous pemphigoid, allergic fungal rhinosinusitis, and other inflammatory conditions. For many patients, Dupixent has provided real relief where other treatments failed. But for some patients, the story has been very different.

The lawsuits allege that Regeneron and Sanofi failed to warn doctors and patients that cutaneous T-cell lymphoma, often called CTCL, can mimic eczema and that Dupixent may mask, accelerate, or delay diagnosis of an underlying lymphoma. Plaintiffs argue that patients with adult-onset, atypical, or treatment-resistant dermatitis should have been warned to rule out lymphoma before starting Dupixent and to stop and investigate if symptoms worsened or changed during treatment.

Our lawyers are reviewing cases involving Dupixent users later diagnosed with CTCL, peripheral T-cell lymphoma, mycosis fungoides, or Sézary syndrome, especially where the patient developed swollen lymph nodes, worsening skin disease, systemic symptoms, chemotherapy, radiation, photopheresis, or stem cell transplant after treatment.

Page written by Ronald V. Miller Jr. This page is for patients and families trying to understand the connection between Dupixent and T-cell lymphoma, the federal MDL, and potential civil claims.

Call us today at 800-553-8082 or get a free online consultation if you or a loved one developed T-cell lymphoma after taking Dupixent.

July 2026 Update: CTCL Cases Centralized in New Jersey MDL

The lymphoma lawsuits are now centralized in federal court. On June 4, 2026, the JPML created MDL No. 3180, In re: Dupixent (Dupilumab) Products Liability Litigation, and transferred the federal cases to the District of New Jersey before Judge Zahid N. Quraishi. As of July 1, there are 26 filed claims in the MDL

The MDL is focused on claims that the drug caused patients to develop CTCL or accelerated preexisting CTCL. The JPML order also recognized that plaintiffs allege common questions involving the science, what the defendants knew, when they should have known it, and whether they provided adequate warnings.

This is not a Dupixent class action lawsuit. In a class action, one or a few plaintiffs represent an entire group, and the result usually applies to everyone in the class unless they opt out. An MDL works differently. Each plaintiff keeps an individual lawsuit, with individual medical history, injury severity, damages, and settlement value. The cases are grouped together for coordinated discovery, expert challenges, motions, and pretrial rulings.

MDL Issue	Current Status	What It Means for Plaintiffs
MDL number	MDL No. 3180	Federal CTCL cases now have a coordinated litigation track.
Court	District of New Jersey	This is where common federal pretrial issues will be handled.
Judge	Judge Zahid N. Quraishi	One judge will manage discovery, motions, expert issues, and eventually bellwether planning if the litigation moves that far.
Main injury	CTCL and CTCL subtypes	Claims involving PTCL or other T-cell lymphomas may be addressed later through the conditional transfer process.

The MDL structure is usually the best path for plaintiffs with serious injuries because it allows coordinated discovery against the defendants while preserving individual damages. A patient with advanced CTCL, chemotherapy, stem cell transplant, or wrongful death has a very different case than someone with a shorter and less severe disease course.

Who May Qualify for a Lawsuit?

Our attorneys are reviewing cases from patients who received Dupixent and were later diagnosed with T-cell lymphoma. You do not need to know whether the drug caused the lymphoma before calling. The first step is a medical record review, including dermatology notes, biopsy reports, pathology, oncology records, prescription history, and treatment timeline.

Cases Our Lawyers Are Reviewing

Drug use before a CTCL, PTCL, mycosis fungoides, or Sézary syndrome diagnosis
Adult-onset eczema or dermatitis before treatment
Initial improvement followed by worsening disease
Swollen lymph nodes, worsening rash, plaques, tumors, or systemic symptoms after treatment
Chemotherapy, radiation, photopheresis, stem cell transplant, or other serious cancer treatment
Wrongful death after a T-cell lymphoma diagnosis

You may qualify if you were prescribed the medication for eczema, asthma, chronic rhinosinusitis, eosinophilic esophagitis, prurigo nodularis, COPD, bullous pemphigoid, allergic fungal rhinosinusitis, or another approved condition and were later diagnosed with a T-cell lymphoma.

Diagnosis	Why It Matters
CTCL	The central injury in the current federal MDL.
Mycosis fungoides	The most common CTCL subtype and one of the diagnoses most often confused with eczema.
Sézary syndrome	An aggressive CTCL subtype involving skin, blood, and lymph nodes.
PTCL	Peripheral T-cell lymphoma may be investigated, but the JPML has not yet decided whether non-CTCL cases belong in the MDL.

Not every patient with lymphoma will qualify. But if you received injections and were later diagnosed with any form of T-cell lymphoma, your case deserves careful review.

Who Probably Does Not Have a Strong Case?

A Dupixent case is weaker if the patient took the drug but was never diagnosed with CTCL, PTCL, mycosis fungoides, Sézary syndrome, or another T-cell lymphoma. A temporary rash, eye irritation, conjunctivitis, a typical eczema flare, or a short-term side effect is not the injury our lawyers are focused on in this litigation.

A case may also be difficult if the CTCL diagnosis clearly predated treatment, if the patient took only one or two doses with no meaningful timing connection, or if the records show no worsening, delayed diagnosis, systemic symptoms, lymph node involvement, or treatment burden after use.

That does not mean you should screen yourself out if you have a confirmed T-cell lymphoma diagnosis. It means the case needs careful review. The key records are the treatment timeline, dermatology notes, biopsy history, pathology reports, oncology records, and the clinical course before and after the drug.

What Is Cutaneous T-Cell Lymphoma?

Cutaneous T-cell lymphoma is a cancer of the immune system involving malignant T cells that migrate to the skin. In its early stages, CTCL often looks almost indistinguishable from eczema, psoriasis, or other chronic inflammatory skin conditions. It behaves like a wolf in sheep’s clothing, presenting as ordinary rashes, plaques, itching, or redness that flare up and fade away, giving the impression of a manageable skin disorder rather than a developing cancer.

That disguise is what makes CTCL so dangerous. The disease can hide in plain sight for years, with biopsies that come back inconclusive and symptoms that mimic benign skin problems. Like a slow-burning fire behind a wall, CTCL may continue progressing quietly until it finally reveals itself, often at a more advanced stage that is far harder to treat.

The most common forms of CTCL are mycosis fungoides and Sézary syndrome. Both are serious, life-altering conditions that often require lifelong treatment. In advanced cases, they can be fatal.

Why CTCL Gets Misdiagnosed as Eczema

One of the most troubling aspects of these cases is that early CTCL and atopic dermatitis can look nearly identical, even to experienced dermatologists.

Both conditions can present with:

Red, inflamed patches
Itchy, scaly skin
Lichenification, meaning thickened and leathery skin
Fissuring and cracking
Symptoms that flare and fade over time

Early-stage mycosis fungoides, the most common form of CTCL, often appears as flat, scaly patches that respond partially to topical steroids, just like eczema. Biopsies can come back inconclusive. Patients and doctors may assume they are dealing with stubborn dermatitis, not a developing malignancy.

So Dupixent suppresses the visible inflammation. The redness fades. The itching improves. To the patient and prescriber, this looks like the drug is working. But if the underlying condition is CTCL rather than eczema, plaintiffs allege the medication may mask symptoms while the disease continues to advance beneath the surface.

By the time the true diagnosis is made, treatment options may be more limited and outcomes may be worse.

What the Lawsuits Allege

Plaintiffs are making serious allegations against Regeneron and Sanofi. These cases are built primarily on failure-to-warn claims, supported by growing scientific evidence. The gap between the evidence and the warning is wide.

Core Allegations

Dupixent caused, accelerated, or unmasked T-cell lymphoma, depending on the patient. Plaintiffs allege it triggered CTCL or PTCL in some patients, or accelerated disease progression in patients whose early-stage lymphoma was misdiagnosed as eczema.
The manufacturers knew or should have known about the risk. Plaintiffs cite case reports, adverse event data, peer-reviewed studies, and FDA safety-signal activity.
The U.S. label contains no specific warning about CTCL or PTCL. Plaintiffs allege the prescribing information did not adequately warn about CTCL, PTCL, mycosis fungoides, or Sézary syndrome.
Atopic dermatitis and early CTCL can look nearly identical. Plaintiffs argue doctors needed clearer guidance to rule out lymphoma before prescribing the drug in adult-onset, atypical, or treatment-resistant dermatitis cases.
No adequate stop-and-investigate guidance was provided. Plaintiffs allege the companies failed to tell prescribers what to do when symptoms evolved in a way that did not fit ordinary eczema.
Patients would have made different choices with adequate warnings. This is often prescribed for conditions that can be miserable but are usually not life-threatening. Plaintiffs argue many patients would have pursued additional testing, chosen alternative treatment, or never started the drug if warned.

The bottom line is that plaintiffs allege Regeneron and Sanofi prioritized sales of a blockbuster drug over patient safety, and that the result was unnecessary human suffering in patients whose cancer diagnosis was delayed, missed, or worsened.

No one told these patients that what looked like eczema might actually be something far more dangerous.

Medical Evidence Being Cited in CTCL Claims

Several studies, case series, pharmacovigilance reports, and adverse event analyses are being cited in connection with this litigation. Observational database studies have reported higher rates of CTCL diagnoses among patients treated with dupilumab compared to similar patients who were not exposed to the drug.

Other reports describe patients treated for presumed eczema who initially improved, then experienced disease progression consistent with CTCL. These patterns have been discussed in dermatology journals and conferences, particularly in patients with adult-onset or treatment-resistant dermatitis.

No single study proves causation for every patient. Plaintiffs argue that the collective evidence was strong enough to require clearer warnings, screening guidance, and stop-and-investigate instructions for prescribers.

Why the Warning Matters

These lawsuits are not a push to recall Dupixent from the market. The core claim is that doctors and patients were not told what they needed to know. Failure to warn is the spine of these cases.

A manufacturer that knows or should know that a subset of patients with adult-onset or refractory dermatitis may actually harbor early CTCL has a duty to communicate that risk. The practical content of the warning is not complicated: before starting treatment in adults with atypical clinical courses or biopsy-suspicious lesions, consider lymphoma. If the disease evolves in a way that is not typical for eczema, stop and investigate. Do not keep escalating the dosage while hoping the symptoms settle down.

Design defect is less obvious in a biologic drug case than in a mechanical device case, but plaintiffs may still argue that the risk-management design was defective because it lacked guardrails for a known diagnostic gray zone.

In a world where early mycosis fungoides can masquerade as eczema for years, a safer risk-management approach includes prescriber education, biopsy prompts in adult-onset disease, repeat testing when symptoms evolve atypically, and clear stop rules when the clinical course deviates from eczema norms.

Even a low-probability risk demands clear warning, especially when the cost of silence is a cancer diagnosis.

Dupixent Potential Settlement Amounts

Any dollar figures at this stage are speculative. This is new litigation. The science is still being tested, defendants have not been found liable, there are no bellwether verdicts, and the litigation record that usually drives settlement negotiations is still being built. But victims and families deserve a frame of reference, which is why we are willing to speculate about Dupixent settlement amounts

Civil lawsuits assign a dollar value to suffering. The severity of the cancer, burden of treatment, strength of causation, length of delayed diagnosis, and clarity of the manufacturer’s knowledge will shape outcomes. If the medical record shows that the drug played a role in accelerating or masking a lymphoma diagnosis, and if discovery confirms inadequate warnings, the exposure for defendants becomes significant. If the documentation is thin or the disease course is ambiguous, settlement values decline.

Here are early working ranges that may make sense if plaintiffs succeed on the science, warnings, and causation:

Disease Severity	Common Treatment and Impact	Early Working Estimate
Early-stage CTCL	Skin-directed therapies, topical treatment, light therapy, monitoring, partial remission, ongoing surveillance.	$100,000 to $300,000
Moderate disease	Photopheresis, interferon, systemic agents, relapsing disease, work disruption, family impact, ongoing morbidity.	$300,000 to $500,000
Advanced CTCL	Chemotherapy, stem cell transplant consideration, hospitalization, severe quality-of-life decline, economic loss, shortened survival risk.	$500,000 to $1.5 million

Again, this is not some look into a crystal ball. This is just our estimate of how things might play out if these claims are successful.

Also, these figures are not verdict predictions. In a successful trial involving advanced lymphoma, delayed diagnosis, chemotherapy, stem cell transplant, or death, a jury verdict is likely to be much higher. But there are no bellwether verdicts yet, and any settlement range today remains a working estimate at best.

Evidence That Can Support a Dupixent Claim

These cases are record-driven. The strongest Dupixent cases will have a clear timeline showing the skin condition before treatment, the reason the drug was prescribed, what happened during treatment, when symptoms changed, when lymph nodes appeared, when biopsies were done, and when lymphoma was diagnosed.

Record	Why It Matters	What It Can Show
Dermatology records	They show the original diagnosis, symptoms, and reason the drug was prescribed.	Adult-onset dermatitis, treatment-resistant disease, atypical rash, and missed warning signs.
Prescription history	The timing of doses is central to causation.	Start date, number of injections, interruptions, and treatment duration.
Biopsy and pathology reports	These records confirm the diagnosis and may show evolving disease.	Mycosis fungoides, Sézary syndrome, CTCL, PTCL, T-cell clonality, or inconclusive earlier biopsies.
Oncology records	They show disease stage, treatment burden, prognosis, and damages.	Chemotherapy, radiation, photopheresis, transplant evaluation, hospitalizations, and survival risk.
Symptom timeline	The before-and-after story often drives the case.	Initial improvement, worsening rash, lymph nodes, systemic symptoms, and delayed diagnosis.

If the diagnosis is uncertain, an independent pathology review may be important. Some of these cases will turn on whether earlier biopsies should have raised concern for lymphoma before treatment was started or continued.

Latest News and Updates

June 2026

The JPML created the Dupixent MDL in the District of New Jersey. The centralized litigation focuses on CTCL claims. The Panel noted that future expansion to other T-cell lymphomas can be handled through the conditional transfer process.

April 2026

Newly filed complaints continued to allege that the drug either caused, accelerated, or unmasked T-cell lymphoma after treatment for presumed eczema. Several complaints described adult-onset eczema, a short course of injections, swollen lymph nodes, rapid diagnosis of lymphoma, chemotherapy, and stem cell transplant evaluation.

March 2026

Regeneron and Sanofi agreed that federal Dupixent cases should be centralized, although they sought a different venue than plaintiffs. The key fight shifted from whether there should be coordinated litigation to where it should be located and how broad the MDL should be.

February 2026

The MDL proceeding was filed with the JPML as MDL No. 3180. Around the same period, the drug continued to expand commercially and regulatorily with additional FDA-approved uses, while plaintiffs pointed out that the U.S. label still did not contain a specific CTCL warning.

Frequently Asked Questions

Is there a class action lawsuit?

Not really. The federal cases are centralized in an MDL, not a class action. Each plaintiff keeps an individual lawsuit with individual injuries, medical history, damages, and settlement value. This is a better path for plaintiffs than a class action lawsuit, especially if you have a strong claim.

What injuries are these lawsuits focused on?

The Dupixent lawsuits are focused on CTCL and related T-cell lymphoma diagnoses after treatment, including mycosis fungoides, Sézary syndrome, and potentially other T-cell lymphoma subtypes depending on the facts and future MDL rulings.

Does the drug cause CTCL?

That is the disputed scientific question in the Dupixent litigation. Plaintiffs allege that it can cause, accelerate, or unmask CTCL in some patients, and that defendants failed to warn about that risk. Defendants are expected to dispute causation and argue that CTCL can already mimic eczema before the drug is ever prescribed.

What makes a lawsuit stronger?

Strong cases often involve adult-onset dermatitis, atypical or treatment-resistant symptoms, drug use before diagnosis, initial improvement followed by worsening, swollen lymph nodes, delayed lymphoma diagnosis, serious treatment, and pathology confirming CTCL or another T-cell lymphoma.

Are there settlement amounts yet?

No. Our lawyers are usually quick to estimate what we think a settlement might be, but it is just too early for that. Case value will depend on the diagnosis, severity, treatment, proof of causation, warning evidence, state law, and, most importantly, whether plaintiffs succeed on the science.

What records should I gather before calling a lawyer?

Save your prescription records, dermatology records, biopsy reports, pathology reports, oncology records, treatment records, photographs of skin changes, pharmacy records, and a timeline of when symptoms began, improved, worsened, and when lymphoma was diagnosed.

What Should You Do Next?

If you or someone you love developed cutaneous T-cell lymphoma after taking Dupixent, get the case evaluated by a lawyer who understands both the medicine and the litigation. These are not routine drug cases. They involve nuanced clinical histories, immunologic complexity, pathology, and an evolving body of science.

The earlier your records are reviewed, the stronger the foundation becomes, especially in cases where the biopsy history is limited or the initial diagnosis was eczema that never responded the way it should have. A lawyer experienced in drug litigation can help secure the complete medical file, obtain an independent pathology review if necessary, and establish a clear timeline that courts and juries can follow.

If a claim is viable, the next step is preserving your rights under the statute of limitations in your state. That deadline varies, but it often starts running from the time of diagnosis or from the point when a reasonable person should have connected the diagnosis to the drug. The rule depends on the state, but either way, the clock matters.

These cases are unlikely to resolve quickly. But if the science continues to strengthen and the filings continue to build, there is a path to accountability. That path starts with a diagnosis, a timeline, and a decision to act.

Contact Us About Your Claim

If you were diagnosed with CTCL, mycosis fungoides, Sézary syndrome, PTCL, or another T-cell lymphoma after taking Dupixent, our lawyers can review your case for free.

Call us today at 800-553-8082 or request a free online consultation.